Background. Two preparations of
botulinum A toxin (BTX-A) are commercially available for the treatment of palmar
hyperhidrosis (PPH):
Botox (Allergan; 100 U/vial) and
Dysport (Ipsen Limited; 500 U/vial), which are not bioequivalent. Results regarding an appropriate conversion factor between them are controversial. Objectives. This paper aims to compare the efficacy of
Botox and
Dysport in PPH using a conversion factor of 1 : 2.5. Methods. Eight patients with severe PPH received
intradermal injections of
Botox in one palm and
Dysport in the other in the same session. Clinical assessment was performed at baseline and posttreatment for 8 months using Minor's
iodine starch test,
Hyperhidrosis Disease Severity Scale (HDSS), and Dermatology Life Quality Index (DLQI) test. Results. At 3 weeks, a significant decrease in sweating for both preparations was noted which was more pronounced with
Dysport compared with
Botox. At 8 weeks, this difference turned insignificant. Continued evaluation showed similar improvement in both palms with a nonsignificant difference. Patients with longer disease duration were more liable to relapse. Conclusion. The efficacy and safety of
Botox and
Dysport injections were similar using a conversion factor of 1 : 2.5. There was a trend towards a more rapid action after
Dysport treatment but without significant importance.